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Abstract
Human papillomavirus (HPV)-driven cutaneous squamous cell carcinoma (cSCC) is the most common cancer in
immunosuppressed patients. Despite indications suggesting that HPV promotes genomic instability during cSCC
development, the molecular pathways underpinning HPV-driven cSCC development remain unknown. We compared the
transcriptome of HPV-driven mouse cSCC with normal skin and observed higher amounts of transcripts for Porcupine and
WNT ligands in cSCC, suggesting a role for WNT signaling in cSCC progression. We conﬁrmed increased Porcupine
expression in human cSCC samples. Blocking the secretion of WNT ligands by the Porcupine inhibitor
LGK974 signiﬁcantly diminished initiation and progression of HPV-driven cSCC. Administration of LGK974 to mice
with established cSCC resulted in differentiation of cancer cells and signiﬁcant reduction of the cancer stem cell
compartment. Thus, WNT/β-catenin signaling is essential for HPV-driven cSCC initiation and progression as well as for
maintaining the cancer stem cell niche. Interference with WNT secretion may thus represent a promising approach for
therapeutic intervention.
Introduction
Cutaneous squamous cell carcinoma (cSCC) develops from
basal keratinocytes in sunlight-exposed skin and is the
second most frequent cancer in fair-skinned individuals.
HPV-driven cSCC is the most common cancer in immu-
nosuppressed organ transplant recipients (OTR), up to 50%
of those patients develop cSCCs within 10 years after
transplantation [1]. Thus, immunosuppression increases the
risk to develop cSCC by 250-fold [2, 3]. In addition, 80% of
cSCC in OTR are positive for HPV compared with 40% in
non-OTR [4], suggesting a role for HPV in the initiation
and/or progression of cSCC particularly in immunosup-
pressed individuals. This is underscored by a recent report
showing that vaccination against HPV protects against
keratinocyte-derived cancers [5]. Although the main driver
mutations of HPV-negative cSCCs are found in the RAS-
MAPK signaling pathway [6], a role for WNT/β-catenin
signaling has been reported as well [7].
The WNT/β-catenin signaling cascade is essential in
many developmental processes but is also involved in
initiation and progression of many cancer types. Signaling
is initiated by the binding of secreted WNT ligands (WNTs)
to the Frizzled/LRP receptor complexes. Secretion of WNT
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ligands fully depends on their acylation by the acyl-
transferase Porcupine (PORCN) [8, 9]. Binding of WNTs to
Frizzled/LRP triggers a cascade of events, which culminates
in cytoplasmic stabilization and subsequent nuclear trans-
location of β-catenin. In the nucleus, β-catenin associates
with TCF/LEF transcription factors to drive expression of
WNT target genes [10]. WNTs also initiate various β-
catenin independent outputs, some of which may play a role
in cSCC [11].
To investigate the molecular mechanisms underlying the
initiation and progression of HPV-driven cSCC, we used a
mouse model in which UV-induced overexpression of the
HPV8-derived E6 oncogene in keratinocytes drives the
development of a progressive cSCC (Krt14-HPV8(E6); [12,
13]). We found increased expression of WNTs and PORCN
in cSCCs. Furthermore, blocking WNT secretion by a
small-molecule inhibitor of PORCN, LGK974 decreased
the cSCC stem cell compartment and inhibited induction
and progression of cSCC.
Results and discussion
Increased expression of WNT ligands and elevated
WNT/β-catenin signaling are hallmarks of HPV8-E6
driven cSCC
Aberrantly active WNT/β-catenin signaling drives various
epithelial cancers, including non-viral cSCC [14-16]. The
importance of WNT/β-catenin signaling in HPV-driven
tumors is unknown. To investigate this, we used the Krt14-
HPV8(E6) transgenic mouse model for cSCC in which
tumor induction can be triggered by UV-irradiation [13].
We quantiﬁed stabilization of β-catenin and observed an
increased ratio of intracellular (nuclear as well as cyto-
plasmic) β-catenin over membranous β-catenin in SCC
compared to healthy skin (Fig. 1a, left panels, supplemen-
tary Figure 1a, b); increased intercellular presence of β-
catenin is an accepted hallmark for active WNT/β-catenin
signaling [10]. We assume that different densities of stromal
cells in wild type skin and tumor samples are responsible
for the increased background in stromal tumor tissue. We
conﬁrmed elevated WNT/β-catenin signaling by in situ
hybridization for the WNT/β-catenin target gene Axin2 [17]
(Fig. 1a, right panels, supplementary Figure 1c).
In non-viral cSCCs, cancer stem cells (CSC) reside at the
tumor–stroma interface in close proximity to the vasculature
[18] and express, besides EpCAM, several integrins
including integrin β1 (CD29) and α6 (CD49f) [19] as well
as CD34 [14, 19, 20]. Indeed, we found a putative popu-
lation of CSCs that were CD34+ at the tumor–stroma
interface in HPV-driven cSCCs (Supplementary Figure 1d).
SCC-associated CSC often lose epithelial markers and
would therefore not necessarily express KRT6 [21]. In
addition, vascular cells can express CD34 [22], explaining
the positive cells far away from the tumor–stroma inter-
phase. To strengthen the point that we indeed ﬁnd CD34
positive CSCs as described for SCC [19], and that CD34
expression can be used to identify SCC-associated CSCs in
the experimental model, we performed co-staining of CD34
and E-cadherin and found double positive cells in a subset
of CD34-positive cells at the tumor–stroma interphase
(Supplementary Figure 1d).
Importantly, ﬂow cytometry analysis of tumors showed
that EpCAM+ CD34+ CSCs expressed a higher amount of
the WNT/β-catenin target gene and stem cell marker Lgr5
[23], when compared with non-stem cell tumor cells
(EpCAM+ CD34-) or stromal cells (EpCAM−CD34−) (Fig.
1b). Thus, elevated WNT signaling and expression of
LGR5 seem to mark the CSC pool in analogy to what has
been described for non-viral cSCC and colorectal cancer
[14, 24].
To better understand the involvement of WNT/β-catenin
signaling in HPV-driven cSCCs, we compared the tran-
scriptome of established cSCC with that of healthy skin.
Gene ontology analysis [25] suggested that differentially
expressed genes are associated with increased cell motility,
altered cell-matrix adhesion and inﬂammation (Supple-
mentary Figure 2a). Several transcripts that have previously
been associated with non-viral cSCC, such as Fosl1
(encoding Fos-like antigen 1), Ptprz1 (encoding protein
tyrosine phosphatase, receptor type Z1) [1921], as well as
transcripts encoding for metalloproteases (Mmp), were also
upregulated in HPV-driven cSCC (Supplementary Figure
2b), suggesting the existence of common pathways in cSCC
that are independent of disease etiology.
Although no mutations in Hras were reported in the
Krt14-HPV8(E6) cSCC tumor model [13], we found a
signiﬁcant upregulation of the RAS-MAPK-ERK signaling
pathway (Supplementary Figures 2a and 2c). Therefore,
RAS-MAPK-ERK activation seems to represent a common
mechanism associated with cSCC progression together with
elevated WNT/β-catenin signaling.
We did not detect an increase of expression of WNT/β-
catenin signaling target genes. This was not unexpected
because of the very high activity of the WNT pathway in
hair follicles, especially during the hair growth (anagen)
phase [26]. However, consistent with the presence of acti-
vated WNT/β-catenin signaling in HPV-driven cSCCs, we
observed decreased expression of extracellular WNT-
inhibitory factors, including members of the Sfrp (encod-
ing secreted frizzled-like protein)-family, Notum and Dkk
(encoding Dickkopf). We also observed increased expres-
sion of transcripts of some Wnts and Porcn, whose product
is essential for WNT secretion (Supplementary Figure 2d).
Interestingly, there is also evidence that precise regulation
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of this enzyme is required for physiological WNT signaling
[27]. Using in situ hybridization, we conﬁrmed strong
Wnt16 expression in most epithelial tumor cells, whereas
Wnt16 mRNA was below detection levels in healthy skin.
This conﬁrms our RNA-sequencing results, where Wnt16
was one of the most upregulated genes, and also shows that
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Fig. 1 Elevated WNT/β-catenin signaling and increased expression of
WNT ligands are hallmarks of HPV8-E6 driven cSCC. a Left panel:
nuclear accumulation of β-catenin in the invasive front of HPV-driven
cSCCs (black arrowheads). Healthy skin shows membranous expres-
sion of β-catenin (gray arrowhead). Scale bar= 50 µm. Right panel:
in situ hybridization for Axin2 (red stain) shows increased expression
of this WNT/β-catenin signaling target in tumors in comparison with
healthy skin. Nuclei are counterstained with hematoxylin (blue stain).
Samples were collected 4 weeks after tumor induction. Scale bar=
100 μm. Representative samples of a total of four biological replicates
are depicted. b Enhanced amount of Lgr5 transcripts in CSCs
(EpCAM+ CD34+ CD49f+) compared to non-CSC tumor cells
(EpCAM+ CD34-) and stromal cells (EpCAM− CD34− CD49f−)
(upper panel). The Wnt target gene Cd44 shows low expression in the
stroma and high expression in all epithelial tumor cells (lower panel).
Cells from HPV-driven cSCC from two different mice were sorted and
expression was quantiﬁed by qRT-PCR. Samples were collected
4 weeks after tumor induction. Symbols represent individual mice.
This experiment was done once. c In situ hybridization of healthy skin
and HPV-driven cSCC for Wnt16 (red), shows higher expression of
Wnt16 in tumors compared with healthy skin. Asterisks marks
unspeciﬁc chromogen accumulation in sebaceous gland cells. The
section is counterstained with hematoxylin. Scale bar= 50 µm. Sam-
ples were collected 4 weeks after tumor induction. Representative
samples of a total of three biological replicates are depicted. d PORCN
(red) staining in healthy skin and HPV-driven cSCC. E-cadherin
(green) marks epithelial cells, DAPI (blue) marks nuclei. Scale bar=
100 μm. PORCN is mostly expressed in tumor epithelial cells along
the tumor–stroma interphase of the tumor, whereas it is absent from
healthy epidermis. Insets show a larger magniﬁcation of the region
marked by the white square. Samples were collected 4 weeks after
tumor induction. Representative samples of a total of four biological
replicates are depicted. e Overlapping expression of PORCN (green)
and CD34 (red) in healthy skin with hair follicles and tumor tissue is
indicated by arrowheads. Scale bar= 50 μm. Insets show a larger
magniﬁcation of the region marked by the white square. Samples were
collected 4 weeks after tumor induction. Representative samples of a
total of three biological replicates are depicted. f Increased expression
of PORCN (red) in human cSCC in comparison with healthy human
skin. E-cadherin (green) marks epithelial tissue, nuclei are counter-
stained in blue. Scale bar= 100 μm. Insets show a larger magniﬁcation
of the region marked by a white square. Additional pictures are shown
in Supplementary Figure 3. A representative sample of a total of nine
is depicted. Krt14-HPV8(E6) mice were described previously [13] and
were bred to FVB mice (Harlan Laboratories, Envigo) in house. Mice
were kept under speciﬁc pathogen-free conditions at the Laboratory
Animal Services Center at the University of Zurich and 6–8-weeks-
old, sex-matched mice were used for all experiments. To induce cSCC,
~ 4 cm2 of shaved dorsal skin was irradiated with UVA (5 J/cm2) plus
UVB (1 J/cm2) using the UV 802 L Waldmann device. Murine tumor
samples were collected 4 weeks after tumor induction. Experiments
were performed in accordance with the Swiss federal and cantonal
regulations on animal protection and were approved by the Cantonal
Veterinary Ofﬁce Zurich. The Swiss law on animal protection
demands that groups sizes are as small as possible. The clear biological
differences allowed statistical differences with small group sizes. No
animals were excluded from analysis in any experiment. In case of
treatment of mice with established tumors, mice were randomized in
two groups before start of treatment based on tumor size; in all other
cases mice were not randomized. The investigators were not blinded.
Groups were compared with an unpaired Student’s t-test and show the
mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001. Based on comparable
SD similar variance was assumed. The above information applies to all
animal experiments in this report. Human SCC samples (nine samples
in total; three were dedifferentiated, ﬁve were moderately differ-
entiated, one was well-differentiated) were obtained from biobanks
managed by the University Research Priority Project “Translational
Cancer Research” and the research project “Skintegrity”. All material
were surplus biopsies from patients who had signed an informed
consent that was approved by the Cantonal Ethics Commission Zurich
(EK647 and EK800). For ﬂow cytometry and sorting, tumors were
collected in PBS and digested for 2 h at 37 °C in 2.4 mg/ml Dispase
(Roche), cut into pieces and digested again for one hour at 37 °C in
1 mg/ml collagenase Type IV (Worthington Biochemical Corporation)
and 0.1 mg/ml DNase (Sigma-Aldrich). Antibodies against the fol-
lowing proteins were used: CD45.1 (clone A20, BioLegend), CD31
(clone MEC13.3, BioLegend), EpCAM (clone GoH3, BioLegend),
CD34 (clone RAM34, eBioscience). Dead cells were excluded using
Zombie Violet Fixable Viability Kit (BioLegend). Doublets were
excluded by FSC-A versus FSC-H and SSC-A versus SSC-H gating.
Immunohistochemistry on frozen sections was performed on tissue
ﬁxed in 4% PFA for 1 h, left to sink in 30% sucrose and embedded in
OCT. Ten-µm-thick cryosections were blocked for 1 h at RT with
2.5% Hings and 2.5% BSA in 0.1% Tween in PBS (PBST) (blocking
buffer), and then stained with biotin-conjugated anti-CD34 (clone
RAM34, eBioscience) and unconjugated rabbit anti-PORCN (clone
ab105543, Abcam) overnight at 4 °C in blocking buffer. Secondary
antibodies (see below) were added for 1 h in blocking buffer at RT,
then samples were mounted in FluorSave (CalBiochem). Standard
protocols were used for embedding and cutting formalin-ﬁxed paraf-
ﬁn-embedded (FFPE) tissue. After deparafﬁnization, on both mouse
and human samples, antigen retrieval was performed in 10 mM tri-
sodium citrate buffer pH 6. Staining was performed as described above
for frozen sections. The following antibodies were used for mouse and
human FFPE samples: Mouse-anti-β-catenin (clone14, BD transduc-
tion labs), mouse-anti-E-cadherin (BD transduction labs), rabbit anti-
PORCN (Abcam ab105543), rabbit anti-Ki67 (Abcam), rabbit anti-
HMGA2 (SantaCruz), rabbit anti-MMP13 (clone 3H13L17, Thermo-
Fisher), and rabbit anti-phospho-ERK (Cell Signaling). Secondary
antibodies used were goat-anti-mouse AlexaFluor 488 and goat-anti-
rabbit AlexaFluor 555. For the PORCN staining a biotin-labeled goat-
anti-rabbit secondary antibody was used, followed by the ABC kit
(VectaShield), and the Cy3 tyramide ampliﬁcation kit (PerkinElmer).
Staining for nuclear β-catenin was performed with biotin-labeled
secondary antibodies, followed by DAB staining (VectorLabs). When
mouse primary antibodies were used on murine tissues, VectorLabs
MOM kit was used to block endogenous antigens. In situ hybridization
was performed using the RNAscope kit (Advanced Cell Diagnostics)
according to the manufacturer’s instructions. Probes for Axin2 and
Wnt16 were obtained from the same company. For qRT-PCR, RNA
was isolated from sorted cells using the NucleoSpin RNA XS kit
(Machery-Nagel) according to the manufacturer’s instructions. qRT-
PCRs using SybrGreen were performed on cDNA synthesized with the
Roche Transcriptor High Fidelity cDNA Synthesis Kit after RNA
isolation by standard TRI-Reagent protocols. Reactions were per-
formed in triplicates and monitored with the ABI Prism 7900HT
system (Applied Biosystems). The following 5’–3’ primers (Micro-
synth) were used for qRT-PCR. Gapdh, fwd AACTTTGG-
CATTGTGGAAGG, rev ATCCACAGTCTTCTGGGTGG; Lgr5, fwd
CTCCACACTTCGGACTCAACAG, rev
AACCAAGCTAAATGCACCGAAT
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Wnt16 is speciﬁcally upregulated in malignant but not
normal skin epithelial cells (Fig. 1c). This is in agreement
with the observation that elevated WNT16 expression cor-
related with enhanced WNT/β-catenin signaling and con-
sequent cell survival and therapy resistance in prostate
cancer [28, 29].
Recent studies have highlighted the importance of
PORCN for establishment and maintenance of a CSC niche
[30]. We found that epithelial tumor cells at the
tumor–stroma interface, which is where the CSCs reside,
strongly expressed PORCN, whereas stromal cells rarely
did (Fig. 1d). To conﬁrm this, we stained for CD34 in
concert with PORCN and found that the PORCN+ cells
included CD34+ and CD34- cells (Fig. 1e). Thus, PORCN
expression may mark the WNT-rich CSC niche in cSCC as
was described recently for lung adenocarcinomas [30].
To validate the clinical relevance of our ﬁndings, we
investigated PORCN expression in human cSCC and
observed increased expression in 6/6 samples independently
of tumor grade (Fig. 1f, supplementary Figure 3a-f). Fur-
thermore, we stained a commercially obtained tissue micro
array (TMA) containing 76 biopsies of human SCC
(20 stage 1; 53 stage 2; 3 stage 3) and four biopsies of
healthy human skin for PORCN and E-Cadherin and
assessed the presence of PORCN-positive epithelial cells.
We detected PORCN expression in the majority of tumors,
independently of the tumor stage. Speciﬁcally, 80% (17/20)
of stage 1, 76% (40/53) of stage 2 and 100% (3/3) of stage 3
tumors expressed PORCN, whereas healthy skin was
negative (supplementary Figure 3g). As ~20% of tumors in
this TMA did not express PORCN, it might be interesting to
compare the genetic landscape of such tumors to PORCN-
positive tumors to understand whether PORCN-negative
tumors are independent of WNT signaling. Of note,
PORCN expression was mostly restricted to the invasive
front of the tumors, suggesting a role for PORCN in CSC
maintenance and tissue invasion in human cSCC too
(Supplementary Figure 3).
Inhibition of WNT secretion impairs the initiation of
HPV-driven cSCC
To address whether WNT secretion and -signaling are
essential for the initiation of HPV-driven cSCC, we admi-
nistered a small molecule inhibitor of PORCN (LGK974),
which blocks the secretion of all WNTs [31]. LGK974 (or
vehicle) was administered daily per os, starting 1 week prior
to tumor induction (Fig. 2a). Administration of 6 mg/kg
LGK974 or vehicle did not affect the general wellbeing of
mice or the intestinal stem cell compartment, which is most
sensitive to perturbations of WNT/β-catenin signaling [32],
(data not shown).
Treatment with LGK974 prior to the tumor induction
resulted in a signiﬁcant reduction in tumor size in com-
parison to the vehicle-treated control mice (Fig. 2b), sug-
gesting an essential role of PORCN and consequently of
WNTs in the initiation of HPV-driven cSCC. Analysis of
hematoxylin and eosin (H&E)-stained sections conﬁrmed
that UV-induced skin inﬂammation failed to progress to
carcinoma in LGK974-treated mice, whereas characteristic
cSCC lesions were observed in vehicle-treated mice (Fig.
2c). In contrast, the lesions in LGK974-treated mice (Fig.
2b) consisted mainly of keratin whorls reminiscent of dif-
ferentiation and in some cases of hair follicles with normal
morphology (Supplementary Figure 4a, b).
Expression of CSC markers is indicative for malignancy
and loss of stem cells often results in differentiation and
ultimately regression of tumors [33]. WNT/β-catenin sig-
naling is one of the key pathways deﬁning the stem cell
niche in many epithelial tissues and cancers of epithelial
origin [24, 34]. As a next step, we therefore investigated
whether inhibition of WNT secretion has an impact on
CSCs in HPV-driven cSCCs. Thus, we quantiﬁed tran-
scripts by qRT-PCR that are expressed in cSCC stem cells
[14, 19, 20]. We focused on Pthlh (encoding parathyroid
hormone-like hormone), Ptprz1 and Cd44 because of their
association with CSC in a chemically induced model of
cSCC [19, 35, 36]. In addition, Cd44 is a prominent Wnt
target gene [37]. Blocking WNT secretion via LGK974
Fig. 2 Inhibition of WNT secretion by the PORCN inhibitor LGK974
impairs the initiation of HPV-driven cSCC. a Experimental design.
Treatment with LGK974 (6 mg/kg) or vehicle was started 7 days prior
to tumor induction by UV-irradiation. Mice were treated daily until the
end point at day 28. Control mice were treated with vehicle. The
vehicle-treated group consisted of four, the LGK974-treated group of
ﬁve mice. The experiment was performed twice with similar results. b
Representative macroscopic display of a vehicle-treated (left panel)
and LGK974-treated (middle panel) tumor. Tumor weight at endpoint
(right panel). Symbols represent individual mice. c Representative
H&E staining of vehicle-treated (left panel) and LGK974-treated (right
panel) tumors. Scale bar= 100 µm. d Quantiﬁcation of transcripts for
Pthlh, Ptprz1, and Cd44 in LGK974- and vehicle-treated tumors
shows signiﬁcant reduction of markers for tumor malignancy upon
treatment. Symbols represent individual mice. e Representative stain-
ing showing stabilization of β-catenin in cytoplasm and nucleus of
vehicle-treated tumors, whereas it is mostly membrane associated upon
LGK974 treatment (Scale bar= 50 μm). f Representative image of
Axin2 in situ hybridization showing reduced transcripts (red) upon
LGK974- treatment. Nuclei are counterstained with Hematoxylin.
Scale bar= 50 μm. The Porcupine inhibitor LGK974 was applied as
described in ref. [31]. In brief, LGK974 was dissolved in DMSO and
diluted in citrate buffer pH 3 to a ﬁnal concentration of 1 mg/ml. Mice
were treated daily with 6 mg/kg LGK974 or vehicle (20% DMSO in
citrate buffer pH 3) per os. Staining and qPCR Protocols are described
in the legend of Fig. 1. The primers used were Pthlh, fwd
ATCCCCGACGCCTATGTAA, rev GGGGAAAAAGCAATCA-
GAGA; Ptprz1, fwd GCCAGTTGTTGTCCACTGC, rev
CCTTTGAGAACGAATGTGCTT; Cd44, fwd
CTCCTTCTTTATCCGGAGCAC, rev
TGGCTTTTTGAGTGCACAGT
D. Zimmerli et al.
administration resulted in signiﬁcantly reduced expression
of all abovementioned CSC markers (Fig. 2d). Upon treat-
ment with LGK974 we observed a reduction in intracellular
β-catenin staining (Fig. 2e, supplementary Figure 4c), as
well as a reduction of Axin2 expression by in situ hybridi-
zation in regions lacking hair follicles (Fig. 2f, supple-
mentary Figure 4d). We detected no changes in transcripts
of the WNT target genes Axin2 as well as Lgr5 when using
qRT-PCR, which may be explained by the increase in the
number of hair follicles in anagen (Supplementary Figure
4a,b).
To conﬁrm the speciﬁcity of PORCN inhibition, we used
Wnt-C59 [38], another PORCN inhibitor, in the same pre-
treatment experimental setup as described above and
obtained similar results with respect to reduced tumor
growth and inhibition of the Wnt/β-catenin pathway acti-
vation (Supplementary Figure 5a-d).
Together our data suggest that WNT ligands are essential
for the stem cell niche in HPV-driven cSCCs. In support of
these ﬁndings, inhibition of PORCN inhibited also basal
cell carcinoma (BCC) [39] as well as keratoacanthoma
development [40].
WNTs promote progression of HPV-driven cSCC
As preemptive inhibition of WNT secretion signiﬁcantly
reduced the development of HPV-driven cSCC, we inves-
tigated whether blocking WNT secretion also interferes
with tumor progression when started at the time of tumor
induction or after tumors had established.
When we started treatment with LGK974 simultaneously
with tumor induction, we observed increased differentiation
and reduced thickness of the tumor upon treatment, but did
not see complete inhibition of tumor growth (Supplemen-
tary Figure 6). A possible explanation for the inability to
copy the results of the treatment starting before tumor
induction with this experiment is the feature of WNT pro-
teins to remain intact for an extended period of time [32].
Next, we treated established cSCC with LGK974 (Fig.
3a). We observed and quantiﬁed a marked reduction of β-
catenin stabilization in response to LGK974 treatment,
indicative of reduced WNT/β-catenin signaling. This ﬁnd-
ing was corroborated by a reduction in Axin2 expression,
especially at the tumor–stroma interphase (supplementary
Figure 7a, Fig. 3b). Although LGK974-treament did not
macroscopically reduce tumor size, analysis of H&E-
stained sections revealed that LGK974-treated tumors dis-
played a more differentiated morphology than vehicle-
treated tumors (Fig. 3c). A good indicator of reduced
malignancy and the differentiation status of cSCCs is the
increased presence of keratin whorls [41] and a reduced
density of invasive cones [42]. LGK974-treated tumors
showed both: an increased density of keratin whorls and a
loss of invasive cones (Fig. 3c). Furthermore, and in line
with increased differentiation, LGK974-treated tumor cells
proliferated less than control tumors as visualized by sig-
niﬁcantly reduced staining for Ki67 (Fig. 3d and Supple-
mentary Figure 7b). In skin tumors, the direct
proportionality between tumor proliferation and tumor size
is complicated by the different cell types within the tumor
mass. In fact, LGK974-treated tumors display enhanced
differentiation/keratinization, which complicates the
assessment of the actual tumor size. Furthermore, LGK974-
treated tumors are more differentiated and thus contain an
increased amount of keratinized matter (Fig. 3c) formed by
extracellular matrix and keratin, which is dead material.
Together, our ﬁndings indicate that blocking WNT
secretion promotes differentiation, and reduces proliferation
as well as invasive potential of established HPV-driven
cSCC.
PORCN inhibition decreases the malignant potential
of HPV-driven cSCCs
To clarify the downstream effects of PORCN inhibition in
HPV-driven cSCCs, we performed RNA sequencing of
LGK974- and vehicle-treated tumors (Supplementary Fig-
ure 7c). Gene ontology analysis [25] of the top deregulated
transcripts (p < 0.05) showed “regulation of keratinocyte
migration” as the primary hit, which conﬁrms our ﬁndings
of reduced invasiveness and malignancy of the tumors upon
LGK974 treatment (Supplementary Figure 7d). In parti-
cular, we observed a signiﬁcant downregulation of tran-
scripts for matrix metalloproteinases (Mmp9, Mmp10,
Mmp13) and upregulation of the metalloproteinase inhibitor
Timp4 [43] (Supplementary Figure 7e). As expected from
Wnt pathway inhibition, we did not ﬁnd indications of a
reduction in MAPK signaling. Because we performed RNA
sequencing on whole tumor tissues, we cannot draw con-
clusions about whether LGK974 treatment affects tumor
cells, tumor-inﬁltrating cells or both. To conﬁrm some
ﬁndings from the RNA sequencing and to clarify in which
cell types the changes occur, we performed immunohis-
tochemistry for HMGA2 and MMP13. Our observation that
LGK974 treatment reduced the expression of HMGA2 in
tumor cells suggests a tumor-intrinsic effect of PORCN
inhibition (Fig. 3e). The stark reduction of MMP13 in tumor
as well as stromal tissue upon LGK974 administration (Fig.
3e) suggests that PORCN inhibition also affects stromal
cells.
To investigate whether PORCN inhibition inﬂuences
CSCs, we analyzed the cellular composition of control and
LGK974-treated tumors by ﬂow cytometry. Blocking WNT
secretion resulted in the reduction of the CD34+ EpCAM+
CD31− CSC population [19], (Fig. 3f and Supplementary
Figure 7f). This was conﬁrmed by antibody staining for
WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma
CD34 on tumor sections (Supplementary Figure 7g), again
underscoring the importance of WNT secretion for CSC
maintenance and thus tumor growth and malignancy.
We investigated the pathways involved in tumorigenesis
and growth of cSCCs that are driven by HPV. Our ﬁnding
that WNT signaling is crucial for tumorigenesis is in line
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with work on chemically induced cSCCs [14]. Of note, in
the case of cSCCs no prominent activating mutations
downstream of the WNT/β-catenin pathway components
were found [6], in contrast to classical WNT/β-catenin-
dependent cancers like colon carcinomas [10]. WNT/β-
catenin activation in HPV-driven cSCC seems rather to be
reached by upregulation of WNTs and factors such as
PORCN that are required for their secretion. The combi-
nation is apparently crucial to maintain a proper CSC niche.
Compelling evidence in support of this theory comes from a
study by [30], where they show that the CSC niche of lung
adenocarcinomas is maintained by cells expressing high
levels of PORCN. By using PORCN inhibitor on HPV-
driven cSCCs, we show the addiction of these cancers for
WNT secretion. As inhibiting WNT secretion severely
hampers tumorigenesis, PORCN inhibition might thus be a
valuable preventive measure against cSCCs after organ
transplantation and subsequent immunosuppression. The
fact that not only cSCCs, but also lung adenocarcinomas
seem to upregulate PORCN to maintain a CSC niche asks
for further investigation into this matter in further epithelial
tumor types. It also draws attention towards the necessity to
not only check the mutational landscape in tumors but also
to carefully check changes in the transcriptome.
In conclusion, our results provide novel insights into the
molecular details of HPV-driven cSCCs. They also reveal a
possible therapeutic approach to prevent and treat this type
of cancers.
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